Chronic doxorubicin cardiotoxicity modulates cardiac cytochrome P450-mediated arachidonic acid metabolism in rats

Drug Metabolism and Disposition

Volumn 40, Issue 11, 2012, Pages 2126-2135

  Alsaad, Abdulaziz M S ^a   Zordoky, Beshay N M ^a   El Sherbeni, Ahmed A ^a   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (3 ADAMANTAN 1 YL UREIDO) CYCLOHEXYLOXYL] BENZOIC ACID; ARACHIDONIC ACID; BENZOIC ACID DERIVATIVE; BETA ACTIN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 2B1; CYTOCHROME P450 2C11; CYTOCHROME P450 2E1; CYTOCHROME P450 4A1; CYTOCHROME P450 OMEGA HYDROXYLASE; DOXORUBICIN; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; FORMAMIDINE; INTERLEUKIN 6; N HYDROXY N' (4 BUTYL 2 METHYLPHENYL) FORMAMIDINE; OMEGA HYDROXYLASE INHIBITOR; PROTEIN BAX; PROTEIN P53; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANP GENE; ARACHIDONIC ACID METABOLISM; ARTICLE; BAX GENE; BETA ACTIN GENE; BETA MHC GENE; BNP GENE; CARDIOTOXICITY; CHRONIC TOXICITY; CONTROLLED STUDY; CYP1A1 GENE; CYP1B1 GENE; CYP2B1 GENE; CYP2C11 GENE; CYP2E1 GENE; CYP2J3 GENE; CYP4A1 GENE; CYP4A2 GENE; CYP4A3 GENE; CYP4F1 GENE; CYP4F4 GENE; CYP4F5 GENE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; EPHX2 GENE; GENE EXPRESSION; GENE INDUCTION; HEART; HEART MUSCLE CELL; IL6 GENE; INOS GENE; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; MALE; MARKER GENE; METABOLITE; NONHUMAN; P53 GENE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; TNF GENE;

ALKANE 1-MONOOXYGENASE; ANIMALS; APOPTOSIS; ARACHIDONIC ACID; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DOXORUBICIN; EPOXIDE HYDROLASES; GENE EXPRESSION; HEART; INFLAMMATION; KIDNEY; LIVER; MALE; MICROSOMES; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84867688992     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046631     Document Type: Article

References (48)

1. Aboutabl ME, Zordoky BN, and El-Kadi AO (2009) 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 158:1808-1819.
2. Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, Zhang Y, Chiamvimonvat N, Shyy JY, Hammock BD, et al. (2009) Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA 106:564-569.
3. Amet Y, Zerilli A, Goasduff T, Dréano Y, and Berthou F (1997) Noninvolvement of CYP2E1 in the (omega-1)-hydroxylation of fatty acids in rat kidney microsomes. Biochem Pharmacol 54:947-952. (Pubitemid 27404601)
4. Anwar-Mohamed A, El-Sherbeni AA, Kim SH, Althurwi HN, Zordoky BN, and El-Kadi AO (2012) Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57BL/6 mouse heart. Xenobiotica. doi:10.3109/00498254.2012.693971
5. Anwar-mohamed A, Zordoky BN, Aboutabl ME, and El-Kadi AO (2010) Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res 61:410-418.
6. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, and Spalla C (2000) Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Reprinted from Biotechnology and Bioengineering, Vol. XI, Issue 6, Pages 1101-1110 (1969). Biotechnol Bioeng 67:704-713.
7. Bao Y, Wang X, Li W, Huo D, Shen X, Han Y, Tan J, Zeng Q, and Sun C (2011) 20-Hydroxyeicosatetraenoic acid induces apoptosis in neonatal rat cardiomyocytes through mitochondrial-dependent pathways. J Cardiovasc Pharmacol 57:294-301.
8. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, and Moreira PI (2009) Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16:3267-3285.
9. Certíková Chábová V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerova Z, Vanourkova Z, Kopkan L, Kramer HJ, Falck JR, et al. (2010) Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond) 118:617-632.
10. Chábová VC, Kramer HJ, Vanecková I, Vernerová Z, Eis V, Tesar V, Skaroupková P, Thumová M, Schejbalová S, Husková Z, et al. (2007) Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol 47:145-159. (Pubitemid 47096871)
11. Chaudhary KR, Batchu SN, Das D, Suresh MR, Falck JR, Graves JP, Zeldin DC, and Seubert JM (2009) Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. Cardiovasc Res 83:362-370.
12. Chen S, Garami M, and Gardner DG (1999) Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes. Hypertension 34:1223-1231. (Pubitemid 30002386)
13. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, and Schenkman JB (2004) Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32:840-847. (Pubitemid 38955614)
14. Christiansen S and Autschbach R (2006) Doxorubicin in experimental and clinical heart failure. Eur J Cardiothorac Surg 30:611-616. (Pubitemid 44404103)
15. Cortés-Funes H and Coronado C (2007) Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 7:56-60. (Pubitemid 47339867)
16. Elbekai RH and El-Kadi AO (2006) Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112:564-587. (Pubitemid 44488710)
17. Iber H, Sewer MB, Barclay TB, Mitchell SR, Li T, and Morgan ET (1999) Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab Rev 31:29-41. (Pubitemid 29106650)
18. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694. (Pubitemid 34165207)
19. Ishizuka T, Cheng J, Singh H, Vitto MD, Manthati VL, Falck JR, and Laniado-Schwartzman M (2008) 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther 324:103-110. (Pubitemid 350294158)
20. Kimes BW and Brandt BL (1976) Properties of a clonal muscle cell line from rat heart. Exp Cell Res 98:367-381.
21. Laethem RM, Balazy M, Falck JR, Laethem CL, and Koop DR (1993) Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J Biol Chem 268:12912-12918. (Pubitemid 23182463)
22. Laethem RM, Halpert JR, and Koop DR (1994) Epoxidation of arachidonic acid as an active-site probe of cytochrome P-450 2B isoforms. Biochim Biophys Acta 1206:42-48. (Pubitemid 24153284)
23. Li-Masters T and Morgan ET (2001) Effects of bacterial lipopolysaccharide on phenobarbital-induced CYP2B expression in mice. Drug Metab Dispos 29:252-257. (Pubitemid 32179523)
24. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
25. Lv X, Wan J, Yang J, Cheng H, Li Y, Ao Y, and Peng R (2008) Cytochrome P450 omegahydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol 596:118-126.
26. Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, Patrignani P, Morganti A, Lechi A, and McGiff JC (2008) Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension 51:1379-1385. (Pubitemid 351555953)
27. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gösele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, et al. (2008) Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40:529-537. (Pubitemid 351601216)
28. Morisseau C and Hammock BD (2007) Measurement of soluble epoxide hydrolase (sEH) activity. Curr Protocol Toxicol 33:4.23.1- 4.23.18.
29. Moshal KS, Zeldin DC, Sithu SD, Sen U, Tyagi N, Kumar M, Hughes WM Jr, Metreveli N, Rosenberger DS, Singh M, et al. (2008) Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia. J Cell Physiol 215:771-781. (Pubitemid 351632699)
30. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, and Koh E (2000) Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study. Circulation 102:572-578. (Pubitemid 30639976)
31. Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, and Kroetz DL (2007) Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos 35:1126-1134. (Pubitemid 46956433)
32. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-1279. (Pubitemid 29398616)
33. Outomuro D, Grana DR, Azzato F, and Milei J (2007) Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int J Cardiol 117:6-15. (Pubitemid 46399979)
34. Panigrahy D, Greene ER, Pozzi A, Wang DW, and Zeldin DC (2011) EET signaling in cancer. Cancer Metastasis Rev 30:525-540.
35. Poloyac SM, Tortorici MA, Przychodzin DI, Reynolds RB, Xie W, Frye RF, and Zemaitis MA (2004) The effect of isoniazid on CYP2E1- and CYP4A-mediated hydroxylation of arachidonic acid in the rat liver and kidney. Drug Metab Dispos 32:727-733. (Pubitemid 38821874)
36. Rahman A, Alam M, Rao S, Cai L, Clark LT, Shafiq S, and Siddiqui MA (2001) Differential effects of doxorubicin on atrial natriuretic peptide expression in vivo and in vitro. Biol Res 34:195-206. (Pubitemid 33064683)
37. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
38. Sun CW, Falck JR, Harder DR, and Roman RJ (1999) Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 33:414-418. (Pubitemid 29065694)
39. Swain SM, Whaley FS, and Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869-2879. (Pubitemid 36605157)
40. Takemura G and Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330-352. (Pubitemid 46295436)
41. Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, Miyauchi T, and Yamaguchi I (2006) Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 101:151-158. (Pubitemid 43938766)
42. Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19:670-686.
43. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, et al. (2006) Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103:18733-18738. (Pubitemid 44913479)
44. Zhang Y, El-Sikhry H, Chaudhary KR, Batchu SN, Shayeganpour A, Jukar TO, Bradbury JA, Graves JP, DeGraff LM, Myers P, et al. (2009) Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 297:H37-H46.
45. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, and El-Kadi AO (2010) Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol 242:38-46.
46. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, and El-Kadi AO (2011) Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab Dispos 39:1440-1450.
47. Zordoky BN and El-Kadi AO (2008a) Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells. Vascul Pharmacol 49:166-172.
48. Zordoky BN and El-Kadi AO (2008b) Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab 9:122-128. (Pubitemid 351461001)